Researchers Uncover Molecular Signature to Predict Therapy Response in Leukemia Patient Subset | GenomeWeb

NEW YORK (GenomeWeb) – An international team led by researchers at the University of Michigan has identified a molecular signature that predicts how patients with chronic myelomonocytic leukemia (CMML) respond to at least one of the disease's standard treatments.

In a study published this week in the Journal of Clinical Investigation, the group described its discovery of a pattern of DNA methylation that distinguished those who responded to the drug decitabine from those who didn't in a small cohort of 40 CMML patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.